Horizon Therapeutics plc Announces Positive Topline Data from TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
-- At Week 24, patients treated with TEPEZZA achieved a 2.41 mm reduction in proptosis from baseline compared with 0.92 mm for those receiving placebo -- -- 62% of patients treated with TEPEZZA had... | April 10, 2023
Source: marketscreener.com
